Helixgate

Helixgate

Uncategorized

Q1 earnings take off, Lilly strikes many deals, Regeneron notches historic approval, FDA raises questions

Q1 earnings take off, Lilly strikes many deals, Regeneron notches historic approval, FDA raises questions

Published

on

Sanofi and Novartis kick off the heart of earnings season; Lilly strikes its fourth pact in as many weeks; Regeneron earns landmark approval for a gene therapy for a type of genetic deafness, and also strikes a White House deal; FDA asks Amgen to withdraw Tavneos and, separately, issues Commissioner’s National Priority Vouches to three unnamed psychedelics companies.​ ​Read More

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

First FDA ODAC meeting without Pazdur highlights conceptual challenges with trial

Published

on

The advisory committee meeting—the FDA’s first drug-related adcomm in nine months—could have been a “more conceptual discussion” about the design of AstraZeneca’s Phase 3 trial of camizestrant in HER2-negative advanced breast cancer, former cancer regulator Harpreet Singh told BioSpace.

Continue Reading

Uncategorized

Summit shares descend as PD-1/VEGF asset misses early survival mark

Published

on

Summit Therapeutics planned an early interim progression-free survival readout for HARMONi-3 in the hope of enabling earlier regulatory engagement—but the early analysis delivered disappointment for the company and shareholders.

Continue Reading

Uncategorized

FDA clears Pfizer, Arvinas’ novel breast cancer therapy despite mixed data

Published

on

Veppanu, the first PROTAC therapy approved by the FDA, improved progression free survival by 43% versus AstraZeneca’s Faslodex but showed no such significant benefit in the intention-to-treat analysis.

Continue Reading
Advertisement

Trending